Recent discussions on X about Glaukos Corporation (GKOS) have centered around the company's latest institutional investments and analyst ratings. Several posts highlight the significant increase in stakes by major firms, sparking interest among investors tracking the medical instruments sector. The buzz intensified following news of a reaffirmed 'buy' rating from a prominent research firm, with a noted price target that suggests confidence in future growth.
Conversations on the platform also touch on Glaukos’ innovative product pipeline, with some users pointing to the potential of treatments for ophthalmic conditions as a key driver of interest. While opinions vary, many express curiosity about how recent share acquisitions by institutional investors might signal broader market trends for the company. This ongoing dialogue keeps the stock in the spotlight as a name to watch in the healthcare space.
Note: This discussion summary was generated from an AI condensation of post data.
Glaukos Corporation Insider Trading Activity
Glaukos Corporation insiders have traded $GKOS stock on the open market 5 times in the past 6 months. Of those trades, 0 have been purchases and 5 have been sales.
Here’s a breakdown of recent trading of $GKOS stock by insiders over the last 6 months:
- TOMAS NAVRATIL (CHIEF DEVELOPMENT OFFICER) has made 0 purchases and 2 sales selling 5,142 shares for an estimated $453,620.
- ALEX R. THURMAN (SVP & CHIEF FINANCIAL OFFICER) has made 0 purchases and 3 sales selling 1,520 shares for an estimated $162,398.
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
Glaukos Corporation Hedge Fund Activity
We have seen 183 institutional investors add shares of Glaukos Corporation stock to their portfolio, and 196 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- DEERFIELD MANAGEMENT COMPANY, L.P. removed 1,039,514 shares (-100.0%) from their portfolio in Q2 2025, for an estimated $107,371,401
- WELLINGTON MANAGEMENT GROUP LLP added 953,614 shares (+41.6%) to their portfolio in Q2 2025, for an estimated $98,498,790
- 1832 ASSET MANAGEMENT L.P. removed 723,300 shares (-100.0%) from their portfolio in Q1 2025, for an estimated $71,187,186
- POINT72 ASSET MANAGEMENT, L.P. added 719,262 shares (+inf%) to their portfolio in Q2 2025, for an estimated $74,292,571
- PRIMECAP MANAGEMENT CO/CA/ added 609,523 shares (+50.0%) to their portfolio in Q2 2025, for an estimated $62,957,630
- DRIEHAUS CAPITAL MANAGEMENT LLC removed 473,153 shares (-48.6%) from their portfolio in Q2 2025, for an estimated $48,871,973
- INVESCO LTD. removed 455,024 shares (-31.3%) from their portfolio in Q2 2025, for an estimated $46,999,428
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
Glaukos Corporation Government Contracts
We have seen $266,562 of award payments to $GKOS over the last year.
Here are some of the awards which we have have seen pay out the most over the last year:
- PROS IMPLANT: $42,621
- PROS IMPLANT: $42,621
- PROSTHETICS. SURGICAL IMPLANT: $21,340
- LEFT EYE IDOSE ISENT: $21,340
- RIGHT EYE IDOSE ISENT: $21,340
To track government contracts to publicy traded companies, check out Quiver Quantitative's government contracts dashboard.
Glaukos Corporation Analyst Ratings
Wall Street analysts have issued reports on $GKOS in the last several months. We have seen 8 firms issue buy ratings on the stock, and 1 firms issue sell ratings.
Here are some recent analyst ratings:
- BTIG issued a "Buy" rating on 09/10/2025
- UBS issued a "Buy" rating on 07/31/2025
- Morgan Stanley issued a "Underweight" rating on 05/06/2025
- Stephens & Co. issued a "Overweight" rating on 05/02/2025
- Stifel issued a "Buy" rating on 05/01/2025
- Truist Securities issued a "Buy" rating on 05/01/2025
- Needham issued a "Buy" rating on 05/01/2025
To track analyst ratings and price targets for Glaukos Corporation, check out Quiver Quantitative's $GKOS forecast page.
Glaukos Corporation Price Targets
Multiple analysts have issued price targets for $GKOS recently. We have seen 10 analysts offer price targets for $GKOS in the last 6 months, with a median target of $116.5.
Here are some recent targets:
- Ryan Zimmerman from BTIG set a target price of $118.0 on 09/10/2025
- Larry Biegelsen from Wells Fargo set a target price of $92.0 on 07/31/2025
- Danielle Antalffy from UBS set a target price of $134.0 on 07/31/2025
- Patrick Wood from Morgan Stanley set a target price of $72.0 on 05/06/2025
- Mason Carrico from Stephens & Co. set a target price of $115.0 on 05/02/2025
- Thomas Stephan from Stifel set a target price of $115.0 on 05/01/2025
- Richard Newitter from Truist Securities set a target price of $135.0 on 05/01/2025
This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.
